Genmab ADR (NASDAQ:GMAB) currently has a daily average trading volume of 1.55M but it saw 1429148 shares traded in last market. With a market cap of 13.03B USD, the company’s current market price of $21.19 came falling about -0.42 while comparing to the previous closing price of $21.28. In past 52 weeks, the stock remained buoying in the range of price level as high as $28.96 and as low as $17.24.
Leerink Partners issued its recommendations for the stock as it upgraded the price target for the stock is $27.
Over the week, GMAB’s stock price is moving 4.23% up while it is 2.71% when we observe its performance for the past one month. Year-to-date it is 1.53% up and over the past year, the stock is showing a downside performance of -27.78%.
The company is expected to be releasing its next quarterly report in June, for which analysts forecasted an EPS of 0.34 while estimate for next year EPS is 1.34. In next quarter, company is expected to be making quarterly sales of $6.3B as analysts are expecting the sales for current fiscal year at $23.88B and seeing the company making $27.72B in sales next year. Moreover, analysts are in estimates of $5.97B for current-quarter revenue.
Currently, Genmab ADR’s total number of outstanding shares is 635.50M with 0.01% of that held by the insiders while 10.38% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 20.91% and return on equity (ROE) at 22.69%. It has a price to earnings ratio (P/E ratio) of 12.02 while having a 11.88 of forward P/E ratio. Stock’s beta reads 0.96. Stock has a price to book (P/B) ratio of 2.54 while price to sale or P/S ratio amounts to 4.03. Its return on asset (ROA) is 19.07% on average.
